Menopause Rating Scale Validation: New Evidence From Transplant Patients

Menopause Rating Scale Validation: New Evidence From Transplant Patients and Beyond

A 2026 Mayo Clinic survey of 192 solid-organ transplant recipients found a median Menopause Rating Scale (MRS) score of 8.0 — mild-to-moderate menopause symptoms — yet only 8.9% used menopausal hormone therapy. The study highlights why validated symptom measures matter, and where they still fall short.

What the Menopause Rating Scale Measures and Why Validation Matters

The MRS asks women to rate 11 symptoms — hot flashes, heart discomfort, sleep problems, joint complaints, depressive mood, irritability, anxiety, sexual difficulties, bladder problems, and dryness — on a 0–4 severity scale. Developed in the early 1990s and validated in multiple languages, it produces three domain scores plus a total score. A total of 8.0, as seen in the Mayo cohort, sits in the mild-to-moderate range; scores above 16 typically indicate severe symptoms.

Validation means the instrument reliably measures what it claims: that a question about night sweats actually tracks vasomotor physiology rather than general stress, and that scores are stable across time and populations. The MRS has been validated in dozens of countries and against objective measures such as follicle-stimulating hormone (FSH) levels, whose fluctuation during the menopausal transition is itself linked to health outcomes like bone loss — a connection explored in our article on FSH swings and bone loss.

Transplant Recipients: MRS Reveals Overlooked Symptoms

Researchers at Mayo Clinic Arizona, led by Dr. Francesca Galasso and colleagues across nephrology, transplant surgery, and women’s health, surveyed women who received a solid-organ transplant (kidney, liver, heart, or lung) between 2018 and 2023. Because immunosuppressant drugs, graft dysfunction, and medication side effects can mimic menopause symptoms — night sweats from infection, mood changes from steroids — clinicians often attribute hot flashes and insomnia to the transplant rather than the menopausal transition.

Using the MRS, the team found that symptom severity differed significantly by menopausal stage for vasomotor symptoms (P = .03), sleep disturbances (P = .04), depressive mood (P = .04), and anxiety (P < .001), with perimenopausal women generally reporting more symptoms. This pattern mirrors what validation studies in general populations show: the perimenopause, not the postmenopause, tends to be the symptom peak. The authors noted that the relatively low vasomotor burden compared to earlier literature may reflect under-recognition or misattribution of symptoms to transplant-related factors rather than a genuinely milder experience.

The low MHT uptake (8.9%) is striking. Transplant recipients have historically been excluded from hormone therapy trials, leaving many clinicians cautious — though current evidence reviewed in our summary of 2026 hormone therapy safety reviews suggests individualized MHT remains an option for many women, with transdermal estrogen often preferred for its favorable safety profile.

New Instruments Build on the MRS: The MMBQ-44

Validation science continues to evolve. A 2026 study published in Diagnostics by Dragomir and colleagues at the Victor Babes University of Medicine and Pharmacy in Romania developed the Multidimensional Menopausal Burden Questionnaire (MMBQ-44), a 44-item instrument designed to capture dimensions the MRS covers only briefly — including body image, sexual wellbeing, and psychological burden — and conducted initial psychometric validation in Romanian women. Such work reflects a broader recognition that no single instrument captures every facet of menopausal experience, and that measures validated in one population may behave differently in another.

This population-dependence is exactly why the Mayo transplant study matters: applying a validated tool like the MRS in an understudied group produces the first reliable baseline of symptom burden, replacing clinical impressions with quantifiable data.

What This Means in Practice

For women and clinicians alike, the takeaway is straightforward. Menopausal symptoms in medically complex populations are real, measurable, and often mild to moderate — but they are frequently missed when other conditions dominate the clinical picture. If you are a transplant recipient or managing another chronic condition, asking for menopause-specific screening (the MRS takes about five minutes) can distinguish transplant-related complaints from hormonal ones. Symptom-specific treatments exist: for women who cannot or prefer not to use hormones, neurokinin receptor antagonists offer a non-hormonal option for hot flashes.

The Mayo authors argue that embedding menopause screening into routine transplant follow-up could improve symptom recognition, quality of life, and long-term health outcomes — including bone and cardiovascular health, which deteriorate faster after early or surgical menopause.

Frequently Asked Questions

What is a normal score on the Menopause Rating Scale?

MRS total scores of 0–4 are considered minimal, 5–8 mild, 9–15 moderate, and 16+ severe. The Mayo transplant cohort’s median of 8.0 fell at the boundary of mild and moderate.

Can I take the MRS myself, or does a doctor need to administer it?

The MRS is a self-report questionnaire that takes about five minutes. You can complete it independently and share the results with your clinician to guide treatment discussions.

Why do perimenopausal women report worse symptoms than postmenopausal women?

Hormone levels fluctuate erratically during perimenopause, which tends to produce more hot flashes, sleep disruption, and mood symptoms than the stable low-estrogen state of postmenopause — a pattern confirmed in both the Mayo study and general-population data.

Is menopausal hormone therapy safe for transplant recipients?

Evidence is limited because transplant recipients have been excluded from most MHT trials, which explains low use (8.9% in the Mayo study). Decisions require individualized discussion of risks with the transplant team.

Validated measurement tools turn the invisible, subjective experience of menopause into data clinicians can act on. As the Mayo study shows, even in complex populations, the right questionnaire can reveal symptoms that routine care overlooks — and open the door to treatment.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42684863/
https://pubmed.ncbi.nlm.nih.gov/42650976/
https://pubmed.ncbi.nlm.nih.gov/42414431/
https://pubmed.ncbi.nlm.nih.gov/42372113/
https://pubmed.ncbi.nlm.nih.gov/42354328/